You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 56 No. 6, December 1956 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effects of a New Drug, Nylidrin, upon the Electroretinogram

JERRY HART JACOBSON, M.D.; DEMIR BASAR, M.D.

AMA Arch Ophthalmol. 1956;56(6):865-868.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Henkes1 originally demonstrated that vasodilator drugs can increase the amplitude of the b-wave of the electroretinogram. Upon the basis of this observation we studied the effects of several vasodilator drugs, as well as the effects of stellate ganglion block, upon the ERG. These results were published a short time ago.2

Recently, we undertook an analysis of the effects, upon the ERG, of a new drug, nylidrin hydrochloride (1-[p-hydroxyphenyl]-2-[1-methyl-3-phenylprophylamino] propanol hydrochloride) (Arlidin hydrochloride).

This drug is a synthetic, belonging to the epinephrine-ephedrine group of compounds,3 and has a physiologically interesting triad of action. It increases the circulating blood volume *; it increases cardiac output,4 and it also dilates the small vessels in skeletal muscle.{dagger} This latter action is thought to be due to relaxation of the smooth muscle fibers in the media of the small arteries and arterioles, and the drug is believed to act at . . . [Full Text PDF of this Article]


Author Affiliations

New York

From the Division of Electrophysiology of the Research Department of the New York Eye and Ear Infirmary.


Footnotes

Received for publication May 24, 1956.

The Arlidin used in the study was supplied by the U. S. Vitamin Corporation. The study was supported by grants from the National Society for the Prevention of Blindness and the National Council to Combat Blindness.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1956 American Medical Association. All Rights Reserved.